- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
March 26, 2024Ronald Schutz, Brendan Johnson Named to Forbes Top 200 Lawyers in the United States
-
March 21, 2024Robins Kaplan Firm Members Appointed to Law360 Editorial Boards
-
March 20, 2024Brandon Vaughn Inducted into The International Society of Barristers
-
April 5, 2024Mass Torts Made Perfect
-
April 17, 2024American Antitrust Institute Virtual CLE Lunch & Learn
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
March 14, 2024How Many Cases Have You Tried to a Verdict?
-
March 2024Do We Have to Share That Information? Attorney-Client Privilege in the Multi-Entity Context
-
March 2024Sellers of a Business: Know Thyself.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Alza Corp. v. Amneal Pharmaceuticals of New York, LLC
Motion for judgment on the pleadings was denied where claim construction and expert discovery was necessary to decide the issue of non-infringement.
July 14, 2017
Case Name: Alza Corp. v. Amneal Pharmaceuticals of New York, LLC, Civ. No. 16-cv-914-RGA, 2017 U.S. Dist. LEXIS 53551 (D. Del. Apr. 7, 2017) (Andrews, J.)
Drug Product and U.S. Patent: Concerta® (methylphenidate); U.S. Patent Nos. 8,163,798 (“the ’798 patent”) and 9,144,549 (“the ’549 patent”)
Nature of the Case and Issue(s) Presented: After Amneal filed its ANDA and a Major Complete Response Amendment with the FDA seeking to sell a generic version of Concerta, Plaintiffs filed this lawsuit claiming infringement of the patents-in-suit. Defendants filed a motion to dismiss requesting judgment on the pleadings under Fed. R. Civ. P. 12(c). The contested claims were of two basic types: (i) non-osmotic and osmotic dosage forms; and (ii) only osmotic dosage forms. As to the claims of category (i), Defendants based their argument on collateral estoppel grounds because the court previously invalidated similar claims for lack of enablement, a decision affirmed by the Federal Circuit. The court dismissed that portion of Defendants’ motion. As to the category (ii) claims, Defendants based their argument on non-infringement arguments. The court denied that portion of Defendants’ motion.
Why Alza Prevailed: The court dismissed the category (i) claims as moot because Alza elected not to assert claims covering non-osmotic dosage forms.
Concerning the category (ii) claims, and relying on the previous trial decision and Federal Circuit affirmance, Amneal argued that the claims requires both a “semipermeable membrane” and a “push layer.” These limitations, according to Amneal, resolved the infringement analysis because its ANDA product would not include a push layer. The court denied Amneal’s motion related to the category (ii) claims for three reasons. First, court found that the Federal Circuit was not engaging in, or reviewing, claim construction because the district court never construed the term “osmotic dosage form.” Second, the court found that the Federal Circuit did not cite, or suggest it was relying on, the specification or any other intrinsic evidence for its description of osmotic dosage forms (because the Federal Circuit was not engaged in claim construction). Third, any description of osmotic dosage forms described in the prior Federal Circuit’s opinion was not necessary to the court’s holding. The enablement dispute focused exclusively on non-osmotic dosage forms, which did not reference a push layer for delineating what was enabled and what was not enabled. The court concluded, “I believe this case requires claim construction and probably expert testimony before a finding on infringement can be made.”
Related Professionals
Miles A. Finn, Ph.D.
Counsel
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.